ArticleThe Lancet regional health. Europe2026
Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: TAK-003 is the first dengue vaccine licensed for endemic and non-endemic regions, but real-world safety data in non-endemic travel settings are scarce, particularly for older adults, people with comorbidities, and concomitant vaccinations. Methods: We conducted a prospective multicentre pharmacovigilance study in eight Spanish travel clinics, enrolling travellers aged ≥4 years who received TAK-003 (January-December 2024). Participants were followed for adverse events (AEs) after each dose. Logistic regression models assessed associations of age, sex, comorbidities, prior flaviviral infection or vaccination history, and concomitant vaccination with risks of any, systemic, or local AEs. Findings: Among 1028 participants (1851 TAK-003 doses), 998 (97.1%) completed ≥1 follow-up assessments; 587/998 (58.8%, 95% CI 55.7-61.8) reported AEs. After the first dose, 470/998 (47.1%, 44.0-50.2) reported AEs, most often injection site pain and swelling, headache, or malaise, declining to 235/679 (34.6%, 31.1-38.3) after the second dose. No serious AEs, anaphylaxis, or deaths occurred. Female sex was associated with any AEs (adjusted OR 1.83, 95% CI 1.42-2.37) and local AEs (1.89, 1.44-2.48). Prior dengue was associated with any (1.51, 1.07-2.14) and systemic AEs (1.73, 1.22-2.43). Concomitant flaviviral vaccination was associated with higher odds of systemic AEs (1.64, 1.18-2.28). Age ≥60 years and comorbidities were not associated with increased reactogenicity. Interpretation: TAK-003 was well tolerated in travellers from non-endemic regions, with no serious AEs reported. Female sex, prior DENV infection, and flaviviral vaccine co-administration were associated with increased reactogenicity; older age, comorbidities, and non-flaviviral vaccine co-administration were not. These findings provide real-world evidence on tolerability of TAK-003 in travellers from non-endemic regions. Larger studies with extended follow-up are needed to better characterise uncommon and longer-term AEs. Funding: No dedicated funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.